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SUMMARY Cisapride is a newly developed substance that stimulates gastrointestinal motility, possibly enhancing acetylcholine release in the gut wall. The aim of our study was to investigate the effect of cisapride on oesophageal motor function in man. In a blind fashion and in random order six healthy volunteers received cisapride (0.5 mg/h intravenously, preceded by a three day oral loading at 10 mg tid) and matching placebo. Oesophageal contractions and lower oesophageal sphincter pressure were constantly recorded during a complete cycle of the interdigestive migrating motor complex and during two and half hours after a mixed test meal. Cisapride did not disturb the interdigestive migrating motor complex. In the fasting state the lower oesophageal sphincter pressure showed considerable interdigestive migrating motor complex phase-related variations, whereas amplitude and duration of the oesophageal contractions did not. In the dosis used cisapride was found to increase lower oesophageal sphincter pressure in the interdigestive and in the late postprandial state, but to have no effect in the early postprandial period. Amplitude and duration of oesophageal contractions were not affected by cisapride.
Cisapride (R 51619, Janssen Pharmaceutica) is a newly developed compound ( Fig. 1) pressure recordings, and the assembly taped to the nose. Side-hole recording orifices at 10 cm above and at 5 cm below the middle of the sleeve sensor measured intraluminal oesophageal pressure and fundic pressure respectively. The catheters were constantly perfused with distilled water at a rate of 1 ml/min, using a low-compliance perfusion system.9 The catheters were connected to external pressure transducers (Hewlett Packard 1280). All signals were recorded on paper using a 6-channel ink writer (Gould) with a paper speed of 25 mm/min. In addition, the signals were recorded on magnetic tape using a Racal-Store 7 with a tape speed of 15/16 inch/s (2.38 cm/s).
CONDUCT OF THE EXPERIMENTS
On the three days preceding each experiment the subjects took 30 mg of cisapride (10 mg tid), or placebo, daily as tablets with identical appearance. Before the experiments the subjects fasted overnight. The pressure transducer assemblies were introduced through the nose. In each arm an intravenous cannula was inserted. Through one cannula cisapride or isotonic saline solution was infused at a constant rate. The dosage of cisapride was 0-5 mg/h. The other cannula was used for blood sampling. The subjects were studied while resting quietly in the supine position. The recordings obtained during the first 60 minutes after insertion of the pressure transducer assemblies and cannulae were not considered.
A complete cycle of the interdigestive migrating motor complex involving the lower oesophageal sphincter, stomach, and duodenum was recorded. When an interdigestive migrating motor complex cycle occurred in the duodenum but not in lower oesophageal sphincter and stomach, this cycle was disregarded and the next one awaited. Blood samples for determination of cisapride concentration were taken in phase I, in phase II, and in phase III replayed from tape and written on paper, using a paper speed of 375 mm/min. Using pencil and ruler, the amplitude of the oesophageal contraction waves was measured, taking the mean end-expiratory oesophageal pressure as baseline. The duration of the contraction waves was measured from the onset of their rapid upward deflection to the end of their rapid downward deflection.
Cisapride plasma concentrations were determined at the laboratories of Janssen Pharmaceutica (Beerse, Belgium), using high-performance liquid chromatography. STATISTICAL 
EVALUA-TION
Results are expressed as mean ± SEM. Differences between placebo and cisapride values were evaluated by paired Student's t tests and by analysis of variance.
Results
Two of the volunteers experienced transient abdominal cramps and some diarrhoea shortly after the ingestion of the first tablet of cisapride. During the following days and during intravenous infusion of cisapride no side-effects were noted. In each subject the cisapride plasma concentrations were constant during the course of the experiment. The mean cisapride level was 37 1±5 7 ng/ml.
In all experiments (placebo and cisapride) interdigestive motor complexes occurred in lower oesophageal sphincter, stomach, and duodenum (Fig. 3) Cisapride increased the interdigestive lower oesophageal sphincter pressure, the increase varying from 36-4±13 4% (phase I) to 27-9±10 4% (phase 11-3). The effect reached statistical significance in phases I, 11-2 and II-3 (paired t tests). The overall effect in the interdigestive state was highly significant (p <0.01, analysis of variance). In the early postprandial periods no effect of cisapride on the lower oesophageal sphincter pressure was observed, but later after the meal cisapride tended to increase the lower oesophageal sphincter pressure. This effect was statistically significant in the last postprandial half-hour period (121-150 min), in which the increase was 37 4±14 3% (Fig. 4) .
The amplitude and duration of the oesophageal contractions did not show any significant variations in time. Mean amplitudes of interdigestive and postprandial oesophageal contractions were 6-29±0-99 and 6-87±0-89 kPa (47-2±7.4 and 51 5±6-7 mm Hg), respectively (placebo values).
Mean durations of interdigestive and postprandial oesophageal contractions were 3-30±0-40 and 3-15±0 37 s. Cisapride had no significant effect on amplitude and duration of the oesophageal contractions (Fig. 5) .
Discussion
In the present study upper gastrointestinal motility in healthy human subjects was recorded during prolonged periods of time, with and without administration of a new prokinetic substance, cisapride. Although this study had not been designed to investigate the effect of cisapride on the interdigestive migrating motor complex in detail, it can be concluded that chronic administration of cisapride does not disturb the cyclic interdigestive 
